Education
Timely Topics in Transplantation Webinar Series
October 21, 2014
Christian Oberkofler, MD • University Hospital Zurich
Thomas Mueller, MD, PhD • University Hospital Zurich
Free to AST members: $25 fee is waived upon logging in during the checkout process.
Whether you missed the World Transplant Congress or simply did not have time to catch all of the sessions, attend this webinar and get the important clinical highlights from the meeting.
After participating in this webinar, the learner will be able to:
- Describe the impact of novel methods of immune monitoring, antibody detection and immune phenotyping on individualized patient treatment
- Discuss living donor safety in respect to current publications and concerns
- Explain surgical innovations in the field of transplantation – organ perfusion systems, laparoscopic/robotic kidney and uterus transplantation
Free to AST members: $25 fee is waived upon logging in during the checkout process.
Whether you missed the World Transplant Congress or simply did not have time to catch all of the sessions, attend this webinar and get the important clinical highlights from the meeting.
After participating in this webinar, the learner will be able to:
- Describe the impact of novel methods of immune monitoring, antibody detection and immune phenotyping on individualized patient treatment
- Discuss living donor safety in respect to current publications and concerns
- Explain surgical innovations in the field of transplantation – organ perfusion systems, laparoscopic/robotic kidney and uterus transplantation
November 15, 2016
Speaker: Jignesh Patel, MD • Cedars-Sinai Heart Institute
Moderator: Monica Colvin, MD, MS • University of Michigan
The presence of donor specific antibodies predisposes the thoracic allograft to the risk of antibody mediated rejection, chronic graft dysfunction and increased mortality. Optimal outcomes depend upon a comprehensive understanding of the significance of circulating antibodies after transplantation. What are the best strategies for defining deleterious antibodies, what are the current available therapies to address these and how effective are they?
After participating in this webinar, the learner will be able to:
- Identify the significance of circulating antibodies in patients awaiting thoracic transplantation or in patients with development of de novo antibodies after transplantation.
- Order appropriate tests to detect relevant donor specific antibodies.
- Design rational therapies for the treatment of post-thoracic transplant circulating antibodies.
May 21, 2014
Read Q&A that wasn't answered during the webinar
Free to AST members: $25 fee is waived upon logging in during the checkout process.
Explore the relevance of HLA testing before and after transplant in solid organ transplantation. At the end of this webinar, participants will be able to:
- Understand the enhanced methods of HLA typing and antibody detection now available before transplant
- Gain insight in determining recipient humoral risk profiles before and after transplant based on available testing
- Appreciate the limitations of HLA testing and the importance of context in interpretation
Explore the relevance of HLA testing before and after transplant in solid organ transplantation.
At the end of this webinar, participants will be able to:
- Understand the enhanced methods of HLA typing and antibody detection now available before transplant
- Gain insight in determining recipient humoral risk profiles before and after transplant based on available testing
- Appreciate the limitations of HLA testing and the importance of context in interpretation
October 18, 2016
- Understand the use and limitations of solid phase assays in identifying anti-HLA antibodies
- Describe the natural history and significance of DSA development post-transplant
- Discuss novel tools to improve specificity of solid phase assays
April 23, 2014
Read Q&A that was not answered during the webinar
Free to AST members: $25 fee is waived upon logging in during the checkout process.
Join a transplant nephrologist, transplant surgeon, and epidemiologist as they discuss the risk of ESRD in living kidney donors focusing on two recent publications in JAMA and Kidney International. The presenters will provide:
- A brief overview of risks of living kidney donation known to date
- Discussion of the study design, methods and statistics in the manuscripts
- Implications of the manuscripts on living kidney donation and how to discuss risk with living donors in the context of this new information
Links to manuscripts:
- Abstract for Risk of End-Stage Renal Disease Following Live Kidney Donation (JAMA subscription required to view full article)
- Long-term Risks for Kidney Donors (Kidney International)
Join a transplant nephrologist, transplant surgeon, and epidemiologist as they discuss the risk of ESRD in living kidney donors focusing on two recent publications in JAMA and Kidney International. The presenters will provide:
- A brief overview of risks of living kidney donation known to date
- Discussion of the study design, methods and statistics in the manuscripts
- Implications of the manuscripts on living kidney donation and how to discuss risk with living donors in the context of this new information
May 17, 2016
Read the Q&A that wasn't answered during webinar
Speaker: Rachel Patzer, PhD • Emory Universtiy
Moderator: Leo Riella, MD, PhD • Harvard Medical School
Significant barriers exist that may prevent patients from successfully navigating the complex transplant process to receive a transplant, including referral for transplant evaluation, starting the transplant evaluation, and completing the steps necessary to be placed on the national deceased donor waiting list or receive a kidney transplantation. There are several strategies and tools that transplant center physicians and staff members can use to improve patient access to transplantation and reduce disparities.
After participating in this webinar, the learner will be able to:
- Understand the key patient- and health system-related barriers in access to multiple steps of the transplantation process
- Evaluate the existing evidence-base of approaches for improving patient readiness and access to transplantation
- Identify potential solutions that transplant centers can implement to reduce disparities in transplantation access
March 19, 2014
Free to AST members: $25 fee is waived upon logging in during the checkout process.
What you'll learn:
- Describe the common targets for direct acting antiviral therapy for HCV
- Understand current side effects and cure rates to therapy for HCV in liver transplant patients
- Discuss all oral DAA drug cocktails for HCV that can and will be used in the near future in transplant patients
What you'll learn:
- Describe the common targets for direct acting antiviral therapy for HCV
- Understand current side effects and cure rates to therapy for HCV in liver transplant patients
- Discuss all oral DAA drug cocktails for HCV that can and will be used in the near future in transplant patients
April 19, 2016
Speaker: Mark Aeder, MD • University Hospitals Case Medical Center
Moderator: Nicole Turgeon, MD • Emory University
The Kidney Allocation System (KAS) was markedly revised on December 4, 2014, resulting in a major early alteration in national kidney distribution. Since a major objective was to provide equity in access to challenged candidates while not compromising vulnerable populations, and allowing for the bolus effects, this presentation will examine first year outcomes and assess the success in meeting the projected KAS goals.
After participating in this webinar, the learner will be able to:
- Identify the changes in kidney transplant distribution across recipient categories
- Distinguish the changes which will be maintained at a new level following the resolution of the initial bolus effect
- Begin to formulate potential modifications to KAS which would further achieve equity in allocation
Moderator: Nicole Turgeon, MD
February 19, 2014
Free to AST members: $25 fee is waived upon logging in during the checkout process.
What You'll Learn:
- Describe OPTN living donor policy requirements for the medical and psychosocial evaluation
- Describe OPTN policy requirements on living donor care, including requirements for follow-up, reporting, and the role of the independent living donor advocate (ILDA)
- Describe strategies to assist programs in monitoring compliance with living donor care requirements
January 26, 2016
Speaker: Daniel Brennan, MD • Washington University School of Medicine
Moderator: Robert Brown, MD • Weill Cornell Medical College
Optimal immunosuppression in organ transplantation is a balance between under immunosuppression, which is associated with graft rejection, and over immunosuppression, which is associated with infection and malignancy. Initial immunosuppression is designed to strike this balance. But how should one adjust immunosuppression when this balance is perturbed and there is an acute infectious complication or malignancy?
After participating in this webinar, the learner will be able to:
- Identify risks for development of acute infectious complications and malignancy in renal transplant recipients.
- Design rational immunosuppression strategies to manage acute infectious complications in renal transplant recipients.
- Design rational immunosuppression strategies to manage malignancy in renal transplant recipients.